Home > News > 77/Myocardial phenotype of patients with indications for secondary prevention implantable cardioverter defibrillator therapy – Insights from cardiovascular magnetic resonance
Arrhythmia
Read Time: < 1 min

77/Myocardial phenotype of patients with indications for secondary prevention implantable cardioverter defibrillator therapy – Insights from cardiovascular magnetic resonance

Published Online: October 3rd 2008 European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr77
Authors: A Zegard (Presenting Author) - Aston University, Birmingham, UK; O Okafor - Aston University, Birmingham, UK; J DeBono - Queen Elizabeth Hospital, Birmingham, UK; M Lencioni - Queen Elizabeth Hospital, Birmingham, UK; M Griffith - Queen Elizabeth Hospital, Birmingham, UK; H Marshall - Queen Elizabeth Hospital, Birmingham, UK; T Qiu - Aston University, Birmingham, UK; F Leyva - Aston University, Birmingham, UK
Quick Links:
Article
Article Information
Article:

Background: Primary prevention implantable cardioverter defibrillator (ICD) therapy is indicated in patients with a LVEF <35%, but most cardiac arrest survivors have a LVEF ≥35%. Increasing evidence suggests that the myocardial phenotype predicts ventricular arrhythmias.

Objective: To determine the cardiovascular magnetic resonance (CMR) characteristics of survivors of sustained ventricular tachycardia (VT) or fibrillation (VF) who underwent secondary prevention ICD or cardiac resynchronisation therapy with defibrillation (CRT-D).

Methods: In this observational study, ECG, coronary angiography, echocardiography and CMR were used for phenotypic characterization prior to ICD or CRT-D therapy. Patients with congenital heart disease, channelopathies, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and chemotherapy-induced cardiomyopathy were excluded.

Results: Patients hospitalised for VF (55.4%) or VT with hemodynamic compromise underwent ICD (71.3%) or CRT-D (28.7%) implantation. Most (56.4%) had no previous history of cardiac disease. At the index hospitalisation, an ischaemic cause was identified in 69.3%, a
non-ischaemic cause in 24.8% and no cause emerged in 5.9%. The LVEF was ≤35% in 55.4% and >35% in 44.6%. Myocardial fibrosis was present in 85.1% (LVEF ≤35%: 91.1%; LVEF >35%: 77.8%; p=0.0619). Myocardial fibrosis was present in 98.6% of patients with ischaemic causes and in 68% with non-ischaemic causes.

Conclusions: Based on LVEF, a large proportion of survivors of sustained VT or VF would not have previously met primary prevention criteria for ICD therapy. In this ‘ICD treatment gap’, myocardial fibrosis was more prevalent than a LVEF≤35%. Prospective studies should on myocardial fibrosis rather than LVEF as an indication for primary prevention ICD therapy.

Article Information:

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72